Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 14, 2022 - Issue
Submit an article Journal homepage
213
Views
0
CrossRef citations to date
0
Altmetric
Original Research

A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin

Oluwadara Olatoke1 HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, CanadaCorrespondence[email protected]
View further author information
,
Vladimir Zah1 HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, CanadaORCID Iconhttps://orcid.org/0000-0003-1368-4491View further author information
ORCID Icon,
Filip Stanicic1 HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, CanadaORCID Iconhttps://orcid.org/0000-0003-2293-8940View further author information
ORCID Icon,
Djurdja Vukicevic1 HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, CanadaORCID Iconhttps://orcid.org/0000-0001-9591-1111View further author information
ORCID Icon,
Platonas Yfantopoulos1 HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, CanadaView further author information
,
Christy Thompson2 Medical Department, Collegium Pharmaceutical Inc., Stoughton, MA, USAView further author information
,
Michael K DeGeorge2 Medical Department, Collegium Pharmaceutical Inc., Stoughton, MA, USAView further author information
&
Steven Passik2 Medical Department, Collegium Pharmaceutical Inc., Stoughton, MA, USAView further author information
 show all
Pages 119-128 | Published online: 03 Mar 2022

References

  • Moorman-Li R, Motycka CA, Inge LD, Congdon JM, Hobson S, Pokropski B. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T. 2012;37(7):412–418.
  • Clauw DJ, Essex MN, Pitman V, Jones KD. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. Postgrad Med. 2019;131(3):185–198. doi:10.1080/00325481.2019.1574403
  • Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16(8):769–780. doi:10.1016/j.jpain.2015.05.002
  • Lowinson JH. Substance Abuse: A Comprehensive Textbook. Lippincott Williams & Wilkins; 2005.
  • Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med. 2009;10(Suppl 2):S79–88. doi:10.1111/j.1526-4637.2009.00666.x
  • McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8(3):181–186. doi:10.1097/00045391-200105000-00006
  • Chung CP, Callahan ST, Cooper WO, et al. Individual short-acting opioids and the risk of opioid-related adverse events in adolescents. Pharmacoepidemiol Drug Saf. 2019;28(11):1448–1456. doi:10.1002/pds.4872
  • Green JL, Bucher Bartelson B, Le Lait MC, et al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend. 2017;175:140–145. doi:10.1016/j.drugalcdep.2017.01.039
  • Food and Drug Administration Center for Drug Evaluation and Research. Abuse-deterrent opioids —evaluation and labeling. Available from: https://www.fda.gov/files/drugs/published/Abuse-Deterrent-Opioids-Evaluation-and-Labeling.pdf. Accessed August 11, 2021.
  • Carinci AJ. Abuse-deterrent opioid analgesics: a guide for clinicians. Pain Manag. 2020;10(1):55–62. doi:10.2217/pmt-2019-0052
  • Green JL, Robbins RS, Dailey-Govoni T, Butler SF. Nonmedical use of Xtampza(®) ER and other oxycodone medications in adults evaluated for substance abuse treatment: real-world data from the Addiction Severity Index-Multimedia Version (ASI-MV(®)). J Pain Res. 2021;14:1773–1783. doi:10.2147/JPR.S304805
  • Geoffrey Severtson S, Kreider SED, Amioka EC, Margolin ZR, Iwanicki JL, Dart RC. Postmarketing analysis of misuse, abuse, and diversion of Xtampza ER. Pain Med. 2020;21(12):3660–3668. doi:10.1093/pm/pnaa272
  • Food and Drug Administration. Product Information - XTAMPZA ER. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208090s000lbl.pdf. Accessed August 19, 2021.
  • Food and Drug Administration. Product information - Oxycontin. Available from: https://www.fda.gov/media/131026/download. Accessed August 19, 2021.
  • Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiatry. 2015;72(5):424–430. doi:10.1001/jamapsychiatry.2014.3043
  • Cicero TJ, Ellis MS, Kasper ZA. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. Pain. 2016;157(6):1232–1238. doi:10.1097/j.pain.0000000000000511
  • Rossiter LF, Kwong WJ, Marrett E. Healthcare resource use and cost: the impact of adopting an abuse-deterrent formulation of extended release Morphine. Clinicoecon Outcomes Res. 2020;12:35–44. doi:10.2147/CEOR.S226607
  • Green T, Perkins M, Kwong J, Jones B. Impact of abuse-deterrent formulation opioid utilization on healthcare resource use among managed medicaid patient. presented at: Academy of Managed Care & Specialty Pharmacy; March 25–28; 2019; San Diego, California. Available from: https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.25.3-a.s1. Accessed August 19, 2021.
  • Institute for Clinical and Economic Review. Opioid epidemic: abuse deterrent opioids. Available from: https://icer.org/assessment/opioids-abuse-deterrent-2017/. Accessed May 28, 2021.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.